|Articles|April 11, 2022
- Pharmaceutical Executive-04-01-2022
- Volume 42
- Issue 4
Pharmaceutical Executive, April 2022 Issue (PDF)
Click the title above for a link to open the Pharmaceutical Executive April 2022 issue in an interactive PDF format.
Advertisement
Articles in this issue
about 4 years ago
Seven Lessons I Learned Working at a Biotech Startupabout 4 years ago
Next-Gen Partnerships: The Ascent of Advanced Therapiesabout 4 years ago
Advantage Pharma: Capitalizing on Workforce Lessonsabout 4 years ago
Diversity in Action: Q&A With Reshma Kewalramaniabout 4 years ago
Diversity in Action: Q&A With Bob McMahonabout 4 years ago
A Dogged Devotionabout 4 years ago
Surviving Biotech’s Longest and Steepest Bear Market Everabout 4 years ago
The Case for Elevating a Brand’s Price Propositionabout 4 years ago
The Impact of Hybrid Workplace Decisions On DE&I DynamicsNewsletter
Lead with insight with the Pharmaceutical Executive newsletter, featuring strategic analysis, leadership trends, and market intelligence for biopharma decision-makers.
Advertisement
Advertisement
Advertisement
Trending on PharmExec
1
Travere Therapeutics’ Filspari Receives Full FDA Approval
2
Regeneron Enters $2.1 Billion Radiopharma Collaboration with Telix Pharmaceuticals
3
FDA Issues CRL to Replimune for RP1 Biologics License Application for Advanced Melanoma Treatment
4
Managing Patient Experience and RWE in Clinical Trials: Q&A with Matt Holms, MB
5